- CDK kinase inhibitors
-
The invention discloses a compound with the general formula (I) and a salt thereof, wherein the compound can be taken as inhibitors of CDK kinase, particularly CDK4/6 kinase, and all variables are defined in the invention. The compound can be used for treating or preventing diseases such as cancer. The present application also relates to pharmaceutical compositions comprising the compound of formula (I).
- -
-
-
- Dipeptidyl peptidase - IV inhibitor, use thereof and intermediate and intermediate preparation method
-
The invention discloses a compound shown as the general formula I or an optical isomer or a pharmaceutically acceptable salt thereof, an application thereof, an intermediate body thereof and a preparation method of the intermediate body thereof. In the formula I, R1, R2, R3, R4, R5 and R6 are defined in the specification. The compounds according to the formula I have the strong inhibition activity and the good selectivity and safety to dipeptidyl peptidase-IV. Thus, the compounds can be used for preparing medicines for treating and preventing dipeptidyl peptidase-IV related diseases.
- -
-
Paragraph 0086; 0093-0094
(2018/07/30)
-
- TGF BETA RECEPTOR ANTAGONISTS
-
The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβ R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
- -
-
Page/Page column 151; 152; 153
(2017/03/08)
-